Is Urolithin A Muscle Health Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Urolithin A Muscle Health Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Background Urolithin A (UA), a gut microbiota-derived metabolite, has been proposed to improve skeletal muscle function, but evidence from randomized controlled trials has not been systematically summarized. [Dao T (2026); evidence level 2] - Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, and the certainty of evidence for the primary quantitatively synthesized outcome was rated using the GRADE approach. [Dao T (2026); evidence level 2] - Conclusion The currently available randomized human evidence is limited to five small, short-term trials in clinically heterogeneous populations. [Dao T (2026); evidence level 2] - This systematic review and meta-analysis aimed to evaluate the effects of UA supplementation on muscle performance as well as biochemical and mitochondrial biomarkers in humans. [Dao T (2026); evidence level 2] - At 5 μM (RNA-seq), UA increased NOTCH1 (+73%), MYMX (+70%), PANX1 (+50%) and MSTN (+64%), and decreased FGF9 (-75%), ICAM5 (-52%) and MRLN (-33%), whereas UB decreased IGFN1 (-75%), TGFBI (-60%) and STC2 (-35%) and increased TGM2 (+59%). [Henrotin Y (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.